Review
Evaluation
Target price
Dynamics
Performance
Growth
Dividends
Risks
CA$ 5.53
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Favourable analyst view
Data is available to registered users only
Data is available to registered users only
About
NervGen Pharma Corp., together with its subsidiaries, engages in the discovery, development, and commercialization of pharmaceutical treatments for medical conditions related to nervous system damage. Its lead product candidate is NVG-291 that is in phase 1 clinical trial for the treatment of spinal cord injuries (SCI), multiple sclerosis, and Alzheimer's disease. The company has a...
Company Valuation
Target Price
The average target price of NGEN.V is 7.7 and suggests 41% upside potential. Usually, this means a BUY recommendation among investment firms, or a recommendation to incre
Data is available to registered users only
Buy
Sell